BioCryst Reports Data From Phase 1 Trial of BCX9930 and Announces Plans to Advance Program Into Proof of Concept Study in PNH Patients
October 28, 2019 06:59 ET
|
BioCryst Pharmaceuticals, Inc.
—Phase 1 data showed rapid, sustained and >95% inhibition of alternative pathway of complement system with 100 mg of oral BCX9930 BID— —BCX9930 safe and generally well tolerated— —Part 1 SAD and...
Biocryst Begins Enrollment of Phase 1 Trial of BCX9930, an Oral Factor D Inhibitor for Complement-Mediated Diseases
June 27, 2019 16:15 ET
|
BioCryst Pharmaceuticals, Inc.
—Data expected in Q4 2019— —BCX9930 showed high potency, specificity, suppression of hemolysis and wide safety margin in preclinical studies— RESEARCH TRIANGLE PARK, N.C., June 27, 2019 (GLOBE...